--Palantir Guides For Full Year 2024 Revenue of $2.677-$2.689 Billion, vs CIQ Analyst Consensus of $2.68 Billion-February 2024-www.financetom.com

--Palantir Guides For Full Year 2024 Revenue of $2.677-$2.689 Billion, vs CIQ Analyst Consensus of $2.68 Billion

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Palantir Guides For Full Year 2024 Revenue of $2.677-$2.689 Billion, vs CIQ Analyst Consensus of $2.68 Billion

May 6, 2024 1:37 PM

04:08 PM EDT, 05/06/2024 (MT Newswires) --

Price: 24.98, Change: -0.24, Percent Change: -0.95

Previous page： -- Tourmaline and Topaz Brief: Upsizing Prior Announced Bought Deal Secondary Offer To $300 Million Next page： -- Dye & Durham Brief: Announcing CEO Succession Plan; Matthew Proud to step down as CEO after transition period

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

-- Tourmaline and Topaz Brief: Upsizing Prior Announced Bought Deal Secondary Offer To $300 Million

Nov 26, 2024

10:25 AM EST, 11/26/2024 (MT Newswires) -- Price: 67.18, Change: -0.86, Percent Change: -1.26 ...

-- Dye & Durham Brief: Announcing CEO Succession Plan; Matthew Proud to step down as CEO after transition period

Nov 26, 2024

10:22 AM EST, 11/26/2024 (MT Newswires) -- Price: 20.69, Change: +2.19, Percent Change: +11.84 ...

-- Dye & Durham Brief: Says "Comprehensive" CEO selection process will be initiated to identify a successor

Nov 26, 2024

10:22 AM EST, 11/26/2024 (MT Newswires) -- Price: 20.54, Change: +2.04, Percent Change: +11.03 ...

UroGen Pharma Says Jelmyto Chemoablation Shows Long-Term Duration of Response in Urothelial Cancer Patients

Nov 26, 2024

10:23 AM EST, 11/26/2024 (MT Newswires) -- UroGen Pharma ( URGN ) said Tuesday that new data from a long-term, follow-up study showed that patients with urothelial cancer who achieved a complete response to primary treatment with the company's Jelmyto chemoablation therapy had a median duration of response of 47.8 months following their initial treatments. The study enrolled 71 patients...